 NEW YORK, Aug. 3, 2021 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor conferences in August: August 9-10: BTIG Virtual Biotechnology Conference 2021. Daniel Vitt, Ph.D. 